+ Watch VCEL
on My Watchlist
The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.
While I am almost 100% skeptical of Garza's pump on biomedreports.com, I do find that ASTM will have a very good chance to demonstrate historical stem cell therapy first in CLI.The interim data (n=46) was significant. But the number of patients was small, treatment time was only 6 months.We will see the whole data set (n=86) on Nov 18. This is a phase IIb, randomized, placebo-controlled, and double-blinded trial. Half of patients will have a treatment of 12 months. We don't have to wait too long to see the data.If the data is significant, ASTM will triple its price. There are numerous cases in biotech that may be called "black swans".As the recent CLI trial by Sanofi/Vical has failed, the significance of ASTM stem cell therapy will be enormous should the data be good.Let's wait and see.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions